PL378367A1 - Sposób leczenia czynnościowych zaburzeń jelit - Google Patents

Sposób leczenia czynnościowych zaburzeń jelit

Info

Publication number
PL378367A1
PL378367A1 PL378367A PL37836704A PL378367A1 PL 378367 A1 PL378367 A1 PL 378367A1 PL 378367 A PL378367 A PL 378367A PL 37836704 A PL37836704 A PL 37836704A PL 378367 A1 PL378367 A1 PL 378367A1
Authority
PL
Poland
Prior art keywords
bowel disorders
functional bowel
treating functional
treating
disorders
Prior art date
Application number
PL378367A
Other languages
English (en)
Inventor
Steven B. Landau
Original Assignee
Dynogen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals, Inc. filed Critical Dynogen Pharmaceuticals, Inc.
Publication of PL378367A1 publication Critical patent/PL378367A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL378367A 2003-01-13 2004-01-13 Sposób leczenia czynnościowych zaburzeń jelit PL378367A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44007703P 2003-01-13 2003-01-13
US49248003P 2003-08-04 2003-08-04

Publications (1)

Publication Number Publication Date
PL378367A1 true PL378367A1 (pl) 2006-04-03

Family

ID=32718145

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378367A PL378367A1 (pl) 2003-01-13 2004-01-13 Sposób leczenia czynnościowych zaburzeń jelit

Country Status (13)

Country Link
US (8) US20040147509A1 (pl)
EP (2) EP1558081A4 (pl)
JP (2) JP2006516976A (pl)
KR (1) KR20050111318A (pl)
CN (1) CN100353946C (pl)
AU (1) AU2004204825B2 (pl)
BR (1) BRPI0406749A (pl)
CA (1) CA2512983A1 (pl)
MX (1) MXPA05007381A (pl)
NZ (1) NZ541008A (pl)
PL (1) PL378367A1 (pl)
WO (1) WO2004062623A2 (pl)
ZA (1) ZA200505817B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
PL378367A1 (pl) * 2003-01-13 2006-04-03 Dynogen Pharmaceuticals, Inc. Sposób leczenia czynnościowych zaburzeń jelit
JP2006516977A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
US6846823B2 (en) * 2003-04-04 2005-01-25 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
JP4725579B2 (ja) * 2005-01-28 2011-07-13 アステラス製薬株式会社 過敏性腸症候群治療薬のスクリーニング方法
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
WO2007005780A2 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
NZ595865A (en) * 2005-10-07 2011-12-22 Colocaps Pty Ltd Preparation for the Treatment of Diarrhoea comprising a bulking agent and diphenoxylate (ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate)
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
EP2120122B1 (en) * 2005-12-02 2013-10-30 iRobot Corporation Coverage robot mobility
US20070254899A1 (en) * 2006-03-31 2007-11-01 Dynogen Pharmaceuticals, Inc. Soluble salts of thieno[2,3-d]pyrimidine derivatives
TW200838534A (en) * 2007-02-07 2008-10-01 Astellas Pharma Inc Treatment for irritable bowel syndrome
KR20110045027A (ko) * 2008-08-28 2011-05-03 아스텔라스세이야쿠 가부시키가이샤 과민성 장 증후군의 치료 방법
WO2013057554A2 (en) * 2011-10-18 2013-04-25 Helsinn Healthcare Sa Therapeutic combinations of netupitant and palonosetron
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
JP6154025B2 (ja) 2012-12-24 2017-06-28 ニューロガストルクス，インコーポレイテッド Ｇｉ管障害を治療するための方法
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
MA40771B1 (fr) 2014-09-29 2021-09-30 Takeda Pharmaceuticals Co Forme cristalline de 1-(1-méthyl-1h-pyrazol -4-yl)-n- ((1r,5s,7s) -9-méthyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
US20240003872A1 (en) * 2020-11-15 2024-01-04 Aphios Corporation Methods for assaying and measuring the efficacy of anti-nausea compounds
CN113412817B (zh) * 2021-05-31 2022-07-12 成都中医药大学附属医院 提高成模率减少死亡率的ibs-d实验动物模型方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US659336A (en) * 1900-05-25 1900-10-09 Charles H Booth Pipe-coupling.
JPS60146891A (ja) * 1984-01-05 1985-08-02 Mitsubishi Chem Ind Ltd 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
DE3885357T2 (de) * 1987-06-29 1994-03-24 Duphar Int Res Anellierte Indolderivate.
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5530008A (en) * 1989-04-21 1996-06-25 Sandoz Ltd. Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
JPH06508836A (ja) * 1991-06-26 1994-10-06 セプラコア，インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
US5262428A (en) * 1992-03-13 1993-11-16 Wake Forest University Biologically active tropane derivatives
EP0632720B1 (en) 1992-03-25 1998-11-11 Depomed Systems, Inc. Hydroxyethylcellulose-based sustained-release oral drug dosage froms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
DE4238553A1 (de) * 1992-11-14 1994-05-19 Kali Chemie Pharma Gmbh Neue Imidazol-1-yl-Verbindungen enthaltende Arzneimittel
JPH0616557A (ja) * 1992-12-21 1994-01-25 Mitsubishi Kasei Corp 脳機能障害改善剤
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
MY113062A (en) * 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
EP0827402A2 (en) * 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
CN1096459C (zh) * 1995-07-28 2002-12-18 大日本制药株式会社 (r)－5－溴－n－(1－乙基－4－甲基六氢－1h－1,4－二氮杂䓬－6－基)－2－甲氧基－6－甲胺基－3－吡啶羧酰胺,其制备方法及含有该化合物的医药组合物
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
WO1997029739A2 (en) * 1996-02-15 1997-08-21 Janssen Pharmaceutica N.V. Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
SE9701304D0 (sv) * 1997-04-09 1997-04-09 Astra Pharma Prod Compounds
PT975327E (pt) * 1997-04-18 2003-11-28 Janssen Pharmaceutica Nv Uso de antagonistas de 5ht3 para estimular a lavagem intestinal
US6177879B1 (en) * 1997-05-09 2001-01-23 Honda Giken Kogyo Kabushiki Kaisha Battery rental system and apparatus
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
DE19734444A1 (de) * 1997-08-08 1999-02-11 Basf Ag 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
US6117879A (en) * 1997-09-16 2000-09-12 Solvay Pharmaceuticals Gmbh Methods of using moxonidine to inhibit nociceptive pain
ATE201598T1 (de) * 1997-09-16 2001-06-15 Solvay Pharm Gmbh Verwendung von moxonidin zur behandlung neuropathischer schmerzen
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6456458B1 (en) * 1998-08-08 2002-09-24 Nidec Corporation Disk-drive motor rotating on a magnetically counterbalanced single hydrodynamic thrust bearing
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
ATE434437T1 (de) * 1999-02-18 2009-07-15 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
JP2002537255A (ja) * 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト リウマチ性炎症性プロセスに対する５−ｈｔ３レセプターアンタゴニストの全身的使用
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
DE19911371A1 (de) * 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
US6448962B1 (en) 1999-05-14 2002-09-10 Three-Five Systems, Inc. Safety timer to protect a display from fault conditions
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
ATE319453T1 (de) * 1999-07-01 2006-03-15 Pharmacia & Upjohn Co Llc Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
AU781718B2 (en) 1999-11-02 2005-06-09 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
EP1251832B1 (en) 2000-02-04 2006-09-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
JP2001243182A (ja) 2000-02-29 2001-09-07 Nec Corp サーバシステム及びＷｅｂコンテンツとサーバシステムとの連動方法
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6566369B2 (en) * 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US6588708B2 (en) * 2001-01-29 2003-07-08 The Boeing Company Spacecraft methods and structures for acquiring and determining power-safe attitudes
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0112494D0 (en) * 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
KR20040020056A (ko) 2001-05-29 2004-03-06 디포메드 디벨롭먼트 리미티드 위식도 역류 질환 및 야간 위산분비의 치료 방법
US6568519B2 (en) 2001-08-10 2003-05-27 Borgwarner, Inc. Torque limiting chain sprocket assembly
US6475078B1 (en) * 2001-10-09 2002-11-05 Norb Borcherding Air ventilating device
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6458795B1 (en) * 2001-11-15 2002-10-01 University Of Florida Method and composition for treatment of irritable bowel disease
CA2473392A1 (en) * 2002-01-18 2003-07-31 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
GB0202265D0 (en) * 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
PT1485078E (pt) * 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
US20040032780A1 (en) * 2002-04-08 2004-02-19 Ehud Langberg System and method for generating a clock signal in a communication system
WO2004004734A1 (en) * 2002-07-10 2004-01-15 Arachnova Therapeutics Ltd. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder
EP1539172A1 (en) * 2002-08-29 2005-06-15 Arachnova Therapeutics Ltd. New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-d]pyrimidine
PL378367A1 (pl) * 2003-01-13 2006-04-03 Dynogen Pharmaceuticals, Inc. Sposób leczenia czynnościowych zaburzeń jelit
JP2006516977A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法

Also Published As

Publication number Publication date
AU2004204825A1 (en) 2004-07-29
ZA200505817B (en) 2006-04-26
EP2286817A2 (en) 2011-02-23
NZ541008A (en) 2007-09-28
US20060217391A1 (en) 2006-09-28
EP2286817A3 (en) 2011-06-15
US20040254168A1 (en) 2004-12-16
AU2004204825B2 (en) 2007-07-19
US20040254169A1 (en) 2004-12-16
US20040254170A1 (en) 2004-12-16
WO2004062623A2 (en) 2004-07-29
JP2011157372A (ja) 2011-08-18
BRPI0406749A (pt) 2005-12-20
MXPA05007381A (es) 2006-02-10
KR20050111318A (ko) 2005-11-24
CA2512983A1 (en) 2004-07-29
WO2004062623A3 (en) 2005-06-09
EP1558081A2 (en) 2005-08-03
US20050192270A1 (en) 2005-09-01
EP1558081A4 (en) 2006-06-14
US20040147509A1 (en) 2004-07-29
US20050032780A1 (en) 2005-02-10
US20040259862A1 (en) 2004-12-23
CN1750759A (zh) 2006-03-22
JP2006516976A (ja) 2006-07-13
CN100353946C (zh) 2007-12-12

Similar Documents

Publication Publication Date Title
PL378367A1 (pl) Sposób leczenia czynnościowych zaburzeń jelit
IL240410A0 (en) Hemolytic disease treatment method
AU2003239489A8 (en) Method of treating dyslipidemic disorders
ZA200508427B (en) Methods for treating interleuking-6 related diseases
EP1683067A4 (en) METHOD FOR THE INVESTIGATION AND TREATMENT OF DISEASES
GB0325192D0 (en) Method of use
IL175818A0 (en) Method for treating adamts-5- associated disease
IL175351A0 (en) Methods of treating asthma
IL163993A0 (en) Method for treating cognitive disorders
GB0302572D0 (en) Method of treatment
GB0306309D0 (en) Method of treatment
PL380068A1 (pl) Sposób obróbki szlamu
EP1493716A4 (en) METHOD OF WASTE WATER TREATMENT
EP1600511A4 (en) METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESS
EP1594473A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF AGE-RELATED DISEASES
GB0208897D0 (en) New method of treatment
GB0217493D0 (en) Novel methods of treatment
GB0221712D0 (en) Methods of treatment
GB0307544D0 (en) Treatment method
GB0327975D0 (en) Methods of treatment
GB0213198D0 (en) Method of treatment
ZA200606071B (en) Methods of treating asthma
GB0302691D0 (en) Treatment method
GB0302657D0 (en) Method of treatment
GB0311123D0 (en) Method of treatment

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)